Surrozen, Inc. is a biotechnology company focused on discovering and developing novel therapeutics based on the modulation of the Wnt pathway, a complex network of proteins known for its pivotal role in cell communication, growth, and regenerative processes. The primary purpose of Surrozen’s research is to innovate therapies that can potentially repair damaged tissues and support tissue maintenance across various diseases. This approach has significant implications for treating chronic conditions and diseases related to tissue degeneration, such as liver diseases and inflammatory bowel diseases. Surrozen's work is particularly impactful in the healthcare and pharmaceuticals sector, aiming to pioneer breakthroughs in medical treatments that could redefine how certain diseases are managed. With its cutting-edge research, Surrozen plays a vital role in advancing the potential of regenerative medicine, striving to address unmet medical needs and contribute to the broader landscape of biotechnological innovation.